13.09.2012 - Sanofi-Pasteur has suffered a setback with its dengue fever vaccine. It proved to be far less effective than originally hoped. But this is not the end of the story.
Results from a Phase IIb study conducted in Thailand revealed the vaccine had about 30% overall efficacy against dengue fever type 2. Originally, the French pharma hoped to achieve more than 70% efficacy. The compound did show strong results against types 1, 3 and 4 of the mosquito-borne disease. However patients with a type 2 infection, the most prevalent strain in Thailand at the time of the study, did not show a satisfactory response. The vaccine candidate is meant to protect against all four types viruses that cause dengue. The result leaves uncertainty on the future of a product that Sanofi estimates it could generate more than €1bn in annual sales. Sanofi has invested €350m in a site to manufacture the vaccine. Still, the vaccine shows promise and Phase III studies involving more than 31,000 children and adults are under way in 10 countries across Asia and Latin America.
Dengue fever, a mosquito-borne disease, also known as "breakbone fever", is a threat to nearly 3 billion people in tropical regions. "This result knocked me off my chair," Scott Halstead, a senior scientific adviser for the non-profit Dengue Vaccine Initiative, who was not involved in the study, told Reuters. Sanofi had already published topline data in July saying that the study had shown efficacy against three of the four strains. However, the company did not present any details. The full findings were published online in the The Lancet. If the Thai trial results had been as strong as expected, Sanofi could have filed for early approval in some countries. Instead, Sanofi now has to wait for the phase III results. A commercial launch can now happen in 2015 or later.
26.05.2016 BigDNA relaunches as Iceni Pharmaceuticals with the aim to develop repurposed and reformulated cancer therapies. First order of business: repurpose Merck Serono’s cilengitide as a multiple myeloma treatment.
24.05.2016 One of the pioneering companies developing pharmaceuticals and diagnostics based on the gut microbiome, Enterome Bioscience, has raised €14.5m in a Series C financing round. Among the investors were Seventure and Lundbeckfond as well as Nestlé.
20.05.2016 The long awaited global review on antimicrobial resistance by economist Lord Jim O’Neill has been published. It sets out an action plan to defeat superbugs with a huge awareness campaign and rapid diagnostics to be used before antibiotics are prescribed.
18.05.2016 Bayer is deepening its involvement in CRISPR with a licensing agreement for genome editing patents. Irish partner ERS Genomics holds the rights to the CRISPR/Cas9 tech from Emmanuelle Charpentier, one of the inventors.
11.05.2016 Newly spun out company OxStem has raised £16.9m (€21.5m) to develop regenerative meds for the treatment of age-related disease. It is the largest financing for an Oxford spin-out – or any UK academic spin-out – to date.
09.05.2016 Swiss Genentech partner AC Immune has raised CHF42.7m (€38.6m) in order to advance its therapeutic and diagnostic product pipeline in Alzheimer’s disease. The news follows a recently announced R&D collaboration with Biogen.
04.05.2016 Barcelona-based epigenetics expert Oryzon Genomics has closed a debt funding round of €10.5m, bringing the total money raised since last year to €27m. The funds will serve to advance the company’s two LSD1 inhibitors in cancer and neurodegeneration.
03.05.2016 Ipsen is strengthening its ties to long-time development partner Oncodesign, a Dijon-based cancer treatment biotech. The French pharma is handing over the pre-clinical pharmacology for its oncology research programmes to Oncodesign.